Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1

JIANGUO CHEN, YANG CHEN and QIYANG HE

Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P.R. China

Received July 25, 2012; Accepted October 1, 2012

DOI: 10.3892/ijo.2012.1668

Abstract. Bleomycin is a first-line clinically used antitumor antibiotic for effective treatment of certain types of cancer in combination with other antitumor agents. Its action is affected by bleomycin hydrolase (BLH), DNA repair enzymes, membrane transport proteins and other cellular factors. To clarify whether BLH confers the resistance to bleomycin in tumor cells, it is necessary to further investigate the roles of BLH and its combination with other factors such as caveolin-1 in the action of bleomycin. In this study fourteen human cell lines were used for determination of bleomycin action and roles of BLH and caveolin-1. The relationship between action of bleomycin and cellular amount of BLH was detected by the MTT method and western blotting in the human leukemia cell line HL-60, HeLa cervical cancer cells and HaCaT immortalized keratinocyte cells. The sensitivity to bleomycin was increased in HeLa cells after knockdown of BLH mRNA by RNA interference. There is no relationship between caveolin-1 levels and action of bleomycin, although the distribution of the cell cycle was altered in the caveolin-1-knockdown HeLa cells after treatment with bleomycin. In addition, regulation of BLH and caveolin-1 expression in HeLa and HaCaT cells was observed in a concentration-dependent manner after exposure to bleomycin. In conclusion, bleomycin hydrolase is one of the biomarkers for determination of bleomycin action. Although caveolin-1 can respond to bleomycin treatment, it is unrelated to bleomycin sensitivity.

Introduction

Bleomycin is first line clinically used antitumor antibiotic, especially in combination with other antitumor agents for effective treatment of several malignant tumors including squamous cell carcinoma, malignant lymphoma and testicular cancer. It exerts its antitumor effects through a sequence-selective, iron-dependent oxidative cleavage of DNA and RNA in the presence of oxygen and finally initiation of the cell death program, such as apoptosis and cellular senescence (1). However, its side actions such as inducing pulmonary fibrosis and flagellate hyperpigmentation retard further application in clinic (2,3). Attempts have been made to develop new superior bleomycin antibiotics to improve antitumor activity and overcome the drawbacks of severe pulmonary toxicity. For instance, the new antibiotic boningycin, a member of bleomycin family, was purified by our institute from the fermentation broth of Streptomyces verticillus var. pingyangensis n.s.p in China. It exhibits antibacterial activities and stronger antitumor activities with lower pulmonary toxicity (4,5).

For the translational development of new bleomycin antibiotic, it is necessary to investigate the biomarkers for prediction of bleomycin sensitivity in tumor cells. Action of bleomycin is affected by bleomycin hydrolase (BLH), DNA repair enzymes, membrane transport proteins, antioxidant enzymes and other cellular factors. Previous studies have confirmed that BLH can hydrolyze the bleomycin to generate the inactive deamino form (6). The mutant mice lacking BLH gene were very sensitive to bleomycin (7). Expression of the yeast BLH gene in the mouse NIH3T3 cells resulted in nearly 5-fold increased resistance to bleomycin (8). Therefore, lower expression of BLH in skin and lung is thought to effectively treat head-neck carcinoma and lead to severe pulmonary toxicity (1,2,9). However, whether BLH can confer the resistance to bleomycin remains controversial. BLH expression level was not well correlated with the resistance to bleomycin in the human bleomycin-resistant cell lines (10). The resistance to bleomycin in yeast was not conferred by overexpression of yeast BLH (11).

Bleomycin action is tissue specific. In clinic chemotherapy for testicular germ cancer, the regimen consisting of bleomycin, cisplatin and etoposide plus surgery techniques has markedly improved the survuval rates from 5% in 1970s to 80% in 2000 (12). It may be mainly contributed by bleomycin as a recent study showed that carnitine transporter hCT2 encoded by the SLC22A16 gene efficiently transferred bleomycin-A5 into the NT2/D1 human testicular cancer cells, leading to extreme sensitivity to bleomycin-A5 (13).

Besides the above mentioned molecules, the action of bleomycin may be affected by other cellular factors such as caveolin-1 (Cav-1). Knockdown of Cav-1 prevented bleomycin-induced growth arrest at the G2/M phase (14). Bleomycin...
treatment of A549 cells resulted in an increased interaction between Cav-1 and MGr1-Ag and a slight enrichment of MGr1-Ag in lipid rafts (15). Overexpression of Cav-1 suppressed bleomycin-induced pulmonary fibrosis in the mice (16). These results indicate that Cav-1 may contribute to the resistance to bleomycin.

In order to explore the biomarkers for determination of bleomycin action, we further evaluated the roles of BLH and cav-1 to bleomycin in the different cell lines. The results showed that BLH conferred the natural resistance to bleomycin in some type of cell lines.

Materials and methods

Drugs and chemicals. Bleomycin, dimethyl sulfoxide, 3, (4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and propidium iodide were purchased from Sigma-Aldrich Chemical Inc. (St. Louis, MO, USA), RPMI-1640, Lipofectamine™ 2000 and Stealth RNA™ siRNA (scrambled siRNA) were obtained from Invitrogen (Carlsbad, CA, USA).

Cell lines and culture. Human hepatoma HepG2 cells, human non-small lung cancer A549 cells, human promyelocytic leukemia HL-60 cells and human cervical cancer HeLa cells were purchased from the American Type Culture Collection (Rockville, MD, USA). Human immortalized keratinocyte HaCaT cells were purchased from Yonsei University (Korea). The normal human hepatocyte L02 cells were purchased from the Institute of Cell Biology (Shanghai, China). The normal human embryo liver HEL cells and human embryo lung fibroblast HPF cells were purchased from Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The cell lines were cultured in RPMI-1640 or DMEM medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. All cultures were maintained in an incubator at 37°C with 5% CO₂ in a humidified atmosphere.

Cytotoxicity assays. Cell viability was assessed using the MTT assay. The cells were seeded into a 96-well plate at a cell density of 3000 per well for 24 h, followed by drug treatment for 72 h. Next, 5 µl of 5 mg/ml MTT was added to the medium and incubated for 2 h at 37°C. After removing the culture medium, 150 µl of dimethyl sulfoxide was added. The plates were read using an enzyme-linked immunosorbent assay plate reader at 570 nm. The viability of untreated cells was set as 100% and the viability in other groups was calculated by comparing the optical density reading with the control. IC₅₀ value was calculated from the nonlinear regression analysis.

Cell cycle analysis by flow cytometry. The cells were trypsinized and washed once with PBS, and then fixed with cold 70% ethanol overnight. The fixed cells were washed twice with PBS and incubated with 100 µg/ml of ribonuclease A at 37°C for 30 min and then stained in PBS containing 50 µg/ml propidium iodide for 1 h. The fluorescence intensity was detected using BD FACSCalibur cytometer (BD Biosciences, CA, USA) and the cell cycle distribution was assayed using the ModFit LT software (BD Biosciences).

Reverse transcriptase-PCR (RT-PCR). The RNA (500 ng) was reverse-transcribed with the Moloney murine leukemia virus reverse transcriptase (Promega Corp., Madison, WI, USA) and oligo(dT)16 primer (Promega) in 20 µl of reaction mixture. The resulting cDNA (1-2 µl) was amplified by PCR for BLH and glyceraldehyde-3-phosphate dehydrogenase. cDNA was amplified in 28-32 cycles, consisting of denaturing for 30 sec at 94°C, annealing for 45 sec at 50°C, and primer extension for 30 sec at 72°C. BLH forward primer: ACCAGCCCATTTGACT TCC and reverse primer: TGTCACCACACCTTCGTG, glyceraldehyde-3-phosphate dehydrogenase forward primer: CGG AGTCAACGGATTGTTGCTGTAT and reverse primer: AGGCC TTCTCCATGTTGTGAAGAC were used for RT-PCR.

Western blot analysis. Cells were lysed with the lysis buffer containing 50 mmol/l Tris-HCl (pH 7.5), 250 mmol/l NaCl, 5 mmol/l EDTA, 50 mmol/l NaF, 1 mmol/l DTT, 1% Triton X-100, 1 mmol/l sodium orthovanadate, and protease inhibitors. After centrifugation, the supernatant fraction was removed and protein concentrations were determined using the Bio-Rad protein assay. Proteins were resolved by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. After blocking with 5% non-fat milk in the blocking buffer (PBS containing 0.1% Tween-20, pH 7.5), the membrane was incubated with the desired primary antibody for 2 h at room temperature and then incubated with an appropriate peroxidase-conjugated secondary antibody. The immunoreactive bands were visualized using the ECL Plus Western Blotting Detection System (Piscataway, NJ, USA). The level of β-actin was used as a loading control. The antibody against Cav-1 were from Cell Signaling Technology, Inc. (Danvers, MA, USA). The antibodies against actin and BLH were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

DNA interference. Cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions using the double-stranded small interfering RNA (siRNA) oligonucleotides (100 pmol siRNA for each gene). Cell treatments were started 24 h after plating. BLH siRNA-3: 5'-UACCC AAAAAUGGACACGCCUCUG-3', Cav-1 siRNA-2: 5'-UU UCCCAACAGCUUAAAGUGG-3'.

Statistical analysis. Data were expressed as means with standard deviations. One-way analysis of variance (ANOVA) was used to analyze the variance for the means of multiple groups. Statistical analysis was performed using SPSS 12.0, and significance was accepted at P<0.01.

Results

Different sensitivities to bleomycin in the cells with high levels of BLH or Cav-1. To explore the relationship between BLH and Cav-1 with bleomycin action, we examined the expression levels of BLH and Cav-1 in fourteen different human cell lines and three distinct cell lines HL-60, HaCaT and HeLa were selected for the further experiment. Western blot analysis confirmed that BLH was indeed strongly expressed in HL-60 cells, whereas its expression was undetectable in HaCaT cells (Fig. 1A and B). By contrast, high Cav-1 amount was detected in HaCaT cells (Fig. 1A and C).
The sensitivity to bleomycin in these cells were determined by MTT assay and plotted on the survival curves (Fig. 1D). The IC$_{50}$ values for HaCaT, HeLa and HL-60 cells were 13.1, 48.2 and 65.8 µM, respectively. HaCaT cells devoid of detectable BLH expression was the most sensitive to bleomycin, suggesting a linear relationship with BLH amount. To further confirm the correlation between BLH or Cav-1 expression and sensitivity to bleomycin, we assessed it by knockdown of BLH or Cav-1 with RNA interference in the cells.

**Knockdown of BLH and Cav-1 expression by RNA interference.**

We designed three different BLH or Cav-1 siRNAs targeted to BLH and Cav-1 mRNA, respectively. The levels of BLH and Cav-1 were analyzed by western blotting after HeLa and HaCaT cells were transfected with siRNAs for 72 h. They were obviously reduced, whereas transfection with scrambled siRNA had no effect (Fig. 2). The BLH siRNA-3 and Cav-1 siRNA-2 with most efficient inhibition were used for the following experiments.

**Reduction of bleomycin action by knockdown of BLH.** To further evaluate whether BLH was involved in modulating bleomycin action, we assessed the sensitivity of HeLa cells to bleomycin following knockdown of BLH with siRNA specific to BLH. The inhibition of BLH mRNA and BLH protein expression reached 73 and 80%, respectively (Fig. 3A). The effect of BLH knockdown with respect to bleomycin action was performed by MTT assay. As illustrated in Fig. 3B, the IC$_{50}$ values of control, scrambled siRNA and BLH siRNA group were 3.63, 3.34 and 0.82 µM, respectively, after exposure to bleomycin for 72 h. The sensitivity to bleomycin increased 3.4-fold after knockdown of BLH, confirming involvement of BLH in modulating bleomycin action.

**Knockdown of Cav-1 was unrelated with sensitivity to bleomycin.** To determine whether Cav-1 conferred resistance to bleomycin, Cav-1 siRNA was used for knockdown of Cav-1. Effective reductions of Cav-1 level were detected by western blot analyses (Fig. 4A and C). Illustrated in Fig. 4B and D, knockdown of Cav-1 did not alter the inhibitory actions of bleomycin towards HeLa and HaCaT cells, indicating that Cav-1 is not involved in the sensitivity to bleomycin.
Change of cell cycle distribution in the Cav-1-knocked down cells treated with bleomycin. In order to further confirm that knockdown of Cav-1 can affect bleomycin action, cell cycle distributions in the HeLa and HaCaT cells were analyzed by flow cytometry following knockdown of Cav-1 and treatment with bleomycin for 24 h. As shown in Fig. 5, knockdown of Cav-1 had no effect on cell cycle in HeLa cells, whereas it reduced S-phase accumulation in HaCaT cells. Cav-1 knockdown followed by 2 µM bleomycin treatment reduced G2/M-phase accumulation from 40.6% in non-transfected HeLa cells to 17.9% in the transfected cells. It was in agreement with a previous observation by Linge et al (14). However, G2/M-phase distribution was slightly reduced in HaCaT cells following Cav-1 knockdown and bleomycin treatment, compared to non-transfected cells.

Action of bleomycin was affected by other cellular factors. In order to explore other cellular factors affecting action of bleomycin except BLH and Cav-1, we compared HeLa and HepG2 cells in which BLH expression levels were similar (Fig. 6A). MTT assay showed that HepG2 cells were more sensitive to bleomycin than HeLa cells (Fig. 6B). As Cav-1 level was different in the two cell lines, knockdown of Cav-1 in HepG2 cells was performed. There was no further increase of sensitivity to bleomycin after reduction of Cav-1 (Fig. 6C and D). The results again indicate that Cav-1 is irrelevant to bleomycin sensitivity, but there are other cellular factors determining it.

We further examined the relationship between expression level of BLH and sensitivity to bleomycin in the cell lines from human lung and liver. Lower level of BLH was detected in human non-small cell lung cancer A549 cells and human embryonic normal lung HPF cells (Fig. 7A). The expression level of BLH in normal embryonic HEL liver cells was lower than that in hepatoma HepG2 and normal immortalized liver L02 cells. The level of Cav-1 in normal embryonic HEL and HPF cells were
Figure 5. The effects on distribution of cell cycle by knockdown of Cav-1. The cells were subjected to cell cycle analysis after knockdown of Cav-1 with RNA interference and bleomycin treatment for 24 h. The concentrations of bleomycin in HeLa and HaCaT cells were 2 and 0.5 µM, respectively. A representative result of three independent experiments is shown.

Figure 6. Action of bleomycin was affected by other cellular factors. (A) The levels of BLH and Cav-1 in HeLa and HepG2 cells were detected by western blotting. (B) Sensitivity of HeLa and HepG2 cells toward bleomycin assayed by MTT. (C) The level of Cav-1 in HepG2 cells was knocked down by Cav-1 siRNA. Lane 1, control; lane 2, scrambled control siRNA; lane 3, Cav-1 siRNA. (D) The cell viability was determined by MTT assay after Cav-1 knockdown and treatment with bleomycin for 72 h. The results were expressed as the mean ± SD from three separate experiments.
higher than that in the other three cell lines. The sensitivity of the five cell types to bleomycin is shown in Fig. 7B and C. Surprisingly, the HEL, A549 and HPF cells containing low BLH level were strikingly more resistant to bleomycin than that in HepG2 and L02 cells. The sensitivity to bleomycin in L02 cells was a little lower than that in HepG2 cells, consistent with the change of BLH level. These findings further supported the notion that besides BLH, other cellular factors could affect the action of bleomycin.

**Discussion**

In this study, we presented evidence to further support the notion that BLH confers resistance to bleomycin. To our knowledge, it is first report that knockdown of BLH markedly increased the sensitivity to bleomycin in HeLa cells. Combining previous reports with our present results, BLH is *bona fide* biomarker for determination of bleomycin action. The conclusion is based on the following evidence. First, high level of BLH in HL-60 cells was closely related with the high resistance to bleomycin, whereas lower level of BLH in HaCaT cells was the most sensitive (Fig. 1). Second, BLH expression could be induced by incubation with bleomycin at sublethal concentrations in HeLa and HepG2 cells which contained moderate amount of BLH (Fig. 8), suggesting that BLH can respond to bleomycin treatment. Third, in clinic chemotherapy, the tumors with low level of BLH such as carcinoma of head and neck and lymphoma and Hodgkin's lymphomas achieve good response to bleomycin treatment (1,17). Fourth, the homozygous variant G/G of BLH gene SNP A1450G is associated with reduced survival in testicular germ cell cancer (18). However, attention should be paid to the complicating situations in which lower level of BLH does not mean more sensitive to bleomycin due to effects of other cellular factors.
Low expression of BLH was observed in A549 and embryo lung fibroblast cells and keratinocyte HaCaT cells, consistent with previous reports (2,19,20). Unexpectedly, A549 and HPF cells have less sensitivity to bleomycin (Fig. 7C), suggesting that BLH is not participating in bleomycin action in lung cells. According to the clinical reports, up to 46% of patients will develop pneumonitis and mortality rate is approximately 3% after administration of bleomycin (21,22), showing individual differences. Therefore, lower level of BLH is not a unique factor to determine the bleomycin-induced pulmonary fibrosis. Several key molecules such as cytosolic phospholipase A2, prostaglandin F2α, receptor, discoidin domain receptor 1 and Cav-1, are reported to be involved in bleomycin-induced pulmonary fibrosis (16,23-25). Knockdown of Nrf-2 obviously augmented cytotoxicity of bleomycin to A549 cells (26). It is clear that other cellular factors except BLH determine cytotoxicity of bleomycin to lung cells.

In liver, the relationship between expression level of BLH and sensitivity to bleomycin is very complicated. Our results showed more sensitivity to bleomycin but BLH level is high in the HepG2 cells (Fig. 7A). In an earlier study, 700-fold survival difference in five rat hepatoma cell lines was observed after treatment with bleomycin (27). Although BLH gene was identified as a methylated tumor suppressor gene in hepatocellular carcinoma, only half of the patients displayed lower BLH expression in hepatocellular carcinoma tissues (28). What determines the different sensitivity to bleomycin in hepatoma and normal cells require further investigation.

In the present results, we have shown that the BLH levels augmented after exposure to bleomycin at sublethal concentrations. It is helpful to explain the reason why induction of bleomycin resistance led to increased BLH activity (29,30). BLH may be a response protein to resist cytotoxicity of bleomycin. However, the BLH activity in bleomycin-resistant sublines was not consistent with the resistance level to bleomycin in human head and neck squamous cell carcinoma A-253 cell line (29), suggesting that BLH is not mainly involved in resistance to bleomycin. Therefore, BLH may play an important role in natural resistance to primary exposure of bleomycin in certain types of cell lines. Several studies reported that Cav-1 expression was involved in the resistance to some anticancer drugs (31,32). The likelihood that Cav-1 mediates sensitivity to bleomycin is ruled out by our present data.

Cav-1, a principal component of caveolae, is found in most mammalian cells including adipocytes, endothelial cells and fibroblasts (33). An important role of caveolin-1 in cellular senescence is demonstrated in vitro by overexpression of Cav-1 in young human diploid fibroblasts and primary cultures of murine fibroblasts (34,35). Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/SP-1 mediated activation of Cav-1 promoter elements (36). Knockdown of Cav-1 can reverse senescent human fibroblasts to re-enter the cell cycle (37). In our experiments, the results with increased level of Cav-1 and disruption of cell cycle distribution after knockdown of Cav-1 are in agreement with a previous study (14). Accumulating data showed that bleomycin can induce cellular senescence in many cell lines (38-40). All the evidence indicate that the role of Cav-1 expression after treatment with bleomycin is to maintain the morphological feature of cellular senescence.

The sensitivity to bleomycin is also mediated by transported proteins in cell membrane. L-carnitine transporter hCT2 was responsible for bleomycin-A5 uptake (17). In the cell lines we studied, the expression of hCT2 mRNA was not detected by RT-PCR (data not shown), ruling out its involvement in bleomycin action. Accumulation data showed that resistance to bleomycin was due to repair enzymes, overexpression of antioxidant enzymes and antioxidant Q10 (30,41). Evaluating all factors reported for prediction of sensitivity to bleomycin is under way in our laboratory.

BLH, a neutral cysteine protease, is associated with other diseases including atop dermatitis, keratinization disorders and Alzheimer’s disease (42-44). It also plays an important role in antigen presentation, hydrolysis of homocysteinethiolactone, breakdown of deaminated filagrin into amino acids N-terminal proteolysis of huntingtin (45-48). Exploring the function of BLH in this study will benefit translational research also in other diseases.

In conclusion, the present data demonstrate that BLH is indeed involved in modulation of bleomycin action, but Cav-1 is not associated with it. It is valuable to take BLH as one of the biomarkers for prediction of individual tumor response to bleomycin treatment. Combining other cellular factors with BLH will more exactly predict the sensitivity to bleomycin and track the tumor responses towards new antibiotics of bleomycin family in clinic trials.

Acknowledgements

This study was supported by grants from the National S&T Major Special Project on Major New Drug Innovation (2012ZX09301002-001), State Mega programs (2010ZX09401-403) and National Scientific Foundation of China (81273553).

References


